Oncolin Therapeutics Signs Agreement with Leading Cancer Center
News Jun 12, 2008
Oncolin Therapeutics, Inc. has announced that it has signed a sponsored research agreement with The University of Texas M. D. Anderson Cancer Center (UTMDACC) in Houston, Texas to support work in the laboratory of Prof. Waldemar Priebe.
This new sponsored research will focus on the development of a new novel class of compounds that inhibit glycolysis, the metabolic pathway essential to the survival of many human tumors.
The company will have a right to an exclusive license to any new patents derived from this research as the company expands its support of Dr. Priebe’s drug discovery and development efforts.
This sponsored research will initially focus on evaluation of the selected lead compounds with the goal of identifying a superior inhibitor of glycolysis that potently blocks tumor growth.
Professor Waldemar Priebe is a world renowned scientist who has several drugs in clinical development based on research from his laboratory and works at UTMDACC, which is the world’s premier cancer center.
“Oncolin is committed to the research in Dr. Priebe’s laboratory in this important area of glycolysis inhibition for cancer treatment. This agreement expands our commitment to this area of cancer research and our goal of bringing the best drug in this therapeutic class into clinical development for patients,” said Dr Donald Picker, Chief Operating Officer of Oncolin.
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019